Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate

Stefan Harmsen, M. Emmy M Dolman, Zoltan Nemes, Marie Lacombe, Bálint Szokol, János Pató, G. Kéri, László Öfi, Gert Storm, Wim E. Hennink, Robbert J. Kok

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Multikinase inhibitors are potent anticancer drugs that simultaneously intervene in multiple related signaling cascades, thus being capable of blocking salvage pathways that may play a role in the development of drug resistance. Multikinase inhibitors are increasingly evaluated for indications other than cancer, but long-term safety risks dictated by off-organ toxicities of these agents may prevent their safe and effective use. Here, we describe a new approach in which platinum coordination chemistry is applied for the development of a cell-selective multikinase inhibitor bioconjugate. The platinum(II) kinase inhibitor bioconjugate was designed to be active with the linker attached to the inhibitor and displayed improved activity by enhanced cell specificity as well as enhanced intracellular retention, thereby prolonging its pharmacological activity. In addition, the utilized platinum-based linkage technology potentiated the inhibitory activity of the multikinase inhibitor. These features in combination with carrier-mediated uptake in the target cells may revolutionize dosing regimens and safety profiles of (multi)kinase inhibitors.

Original languageEnglish
Pages (from-to)540-545
Number of pages6
JournalBioconjugate Chemistry
Volume22
Issue number4
DOIs
Publication statusPublished - Apr 20 2011

Fingerprint

Platinum
Phosphotransferases
Safety
Salvaging
Drug Resistance
Pharmaceutical Preparations
Toxicity
Pharmacology
Technology
Neoplasms

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Organic Chemistry
  • Pharmaceutical Science
  • Biomedical Engineering
  • Pharmacology

Cite this

Harmsen, S., Dolman, M. E. M., Nemes, Z., Lacombe, M., Szokol, B., Pató, J., ... Kok, R. J. (2011). Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate. Bioconjugate Chemistry, 22(4), 540-545. https://doi.org/10.1021/bc1005637

Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate. / Harmsen, Stefan; Dolman, M. Emmy M; Nemes, Zoltan; Lacombe, Marie; Szokol, Bálint; Pató, János; Kéri, G.; Öfi, László; Storm, Gert; Hennink, Wim E.; Kok, Robbert J.

In: Bioconjugate Chemistry, Vol. 22, No. 4, 20.04.2011, p. 540-545.

Research output: Contribution to journalArticle

Harmsen, S, Dolman, MEM, Nemes, Z, Lacombe, M, Szokol, B, Pató, J, Kéri, G, Öfi, L, Storm, G, Hennink, WE & Kok, RJ 2011, 'Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate', Bioconjugate Chemistry, vol. 22, no. 4, pp. 540-545. https://doi.org/10.1021/bc1005637
Harmsen S, Dolman MEM, Nemes Z, Lacombe M, Szokol B, Pató J et al. Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate. Bioconjugate Chemistry. 2011 Apr 20;22(4):540-545. https://doi.org/10.1021/bc1005637
Harmsen, Stefan ; Dolman, M. Emmy M ; Nemes, Zoltan ; Lacombe, Marie ; Szokol, Bálint ; Pató, János ; Kéri, G. ; Öfi, László ; Storm, Gert ; Hennink, Wim E. ; Kok, Robbert J. / Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate. In: Bioconjugate Chemistry. 2011 ; Vol. 22, No. 4. pp. 540-545.
@article{3523ad2dda2d4d6490f3dfe2f3a4debd,
title = "Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate",
abstract = "Multikinase inhibitors are potent anticancer drugs that simultaneously intervene in multiple related signaling cascades, thus being capable of blocking salvage pathways that may play a role in the development of drug resistance. Multikinase inhibitors are increasingly evaluated for indications other than cancer, but long-term safety risks dictated by off-organ toxicities of these agents may prevent their safe and effective use. Here, we describe a new approach in which platinum coordination chemistry is applied for the development of a cell-selective multikinase inhibitor bioconjugate. The platinum(II) kinase inhibitor bioconjugate was designed to be active with the linker attached to the inhibitor and displayed improved activity by enhanced cell specificity as well as enhanced intracellular retention, thereby prolonging its pharmacological activity. In addition, the utilized platinum-based linkage technology potentiated the inhibitory activity of the multikinase inhibitor. These features in combination with carrier-mediated uptake in the target cells may revolutionize dosing regimens and safety profiles of (multi)kinase inhibitors.",
author = "Stefan Harmsen and Dolman, {M. Emmy M} and Zoltan Nemes and Marie Lacombe and B{\'a}lint Szokol and J{\'a}nos Pat{\'o} and G. K{\'e}ri and L{\'a}szl{\'o} {\"O}fi and Gert Storm and Hennink, {Wim E.} and Kok, {Robbert J.}",
year = "2011",
month = "4",
day = "20",
doi = "10.1021/bc1005637",
language = "English",
volume = "22",
pages = "540--545",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - Development of a cell-selective and intrinsically active multikinase inhibitor bioconjugate

AU - Harmsen, Stefan

AU - Dolman, M. Emmy M

AU - Nemes, Zoltan

AU - Lacombe, Marie

AU - Szokol, Bálint

AU - Pató, János

AU - Kéri, G.

AU - Öfi, László

AU - Storm, Gert

AU - Hennink, Wim E.

AU - Kok, Robbert J.

PY - 2011/4/20

Y1 - 2011/4/20

N2 - Multikinase inhibitors are potent anticancer drugs that simultaneously intervene in multiple related signaling cascades, thus being capable of blocking salvage pathways that may play a role in the development of drug resistance. Multikinase inhibitors are increasingly evaluated for indications other than cancer, but long-term safety risks dictated by off-organ toxicities of these agents may prevent their safe and effective use. Here, we describe a new approach in which platinum coordination chemistry is applied for the development of a cell-selective multikinase inhibitor bioconjugate. The platinum(II) kinase inhibitor bioconjugate was designed to be active with the linker attached to the inhibitor and displayed improved activity by enhanced cell specificity as well as enhanced intracellular retention, thereby prolonging its pharmacological activity. In addition, the utilized platinum-based linkage technology potentiated the inhibitory activity of the multikinase inhibitor. These features in combination with carrier-mediated uptake in the target cells may revolutionize dosing regimens and safety profiles of (multi)kinase inhibitors.

AB - Multikinase inhibitors are potent anticancer drugs that simultaneously intervene in multiple related signaling cascades, thus being capable of blocking salvage pathways that may play a role in the development of drug resistance. Multikinase inhibitors are increasingly evaluated for indications other than cancer, but long-term safety risks dictated by off-organ toxicities of these agents may prevent their safe and effective use. Here, we describe a new approach in which platinum coordination chemistry is applied for the development of a cell-selective multikinase inhibitor bioconjugate. The platinum(II) kinase inhibitor bioconjugate was designed to be active with the linker attached to the inhibitor and displayed improved activity by enhanced cell specificity as well as enhanced intracellular retention, thereby prolonging its pharmacological activity. In addition, the utilized platinum-based linkage technology potentiated the inhibitory activity of the multikinase inhibitor. These features in combination with carrier-mediated uptake in the target cells may revolutionize dosing regimens and safety profiles of (multi)kinase inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=79955012078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955012078&partnerID=8YFLogxK

U2 - 10.1021/bc1005637

DO - 10.1021/bc1005637

M3 - Article

VL - 22

SP - 540

EP - 545

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 4

ER -